Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Liabilities (2022 - 2025)

BioXcel Therapeutics has reported Total Liabilities over the past 4 years, most recently at $140.4 million for Q4 2025.

  • Quarterly results put Total Liabilities at $140.4 million for Q4 2025, up 6.8% from a year ago — trailing twelve months through Dec 2025 was $140.4 million (up 6.8% YoY), and the annual figure for FY2025 was $140.4 million, up 6.8%.
  • Total Liabilities for Q4 2025 was $140.4 million at BioXcel Therapeutics, up from $133.7 million in the prior quarter.
  • Over the last five years, Total Liabilities for BTAI hit a ceiling of $154.7 million in Q1 2024 and a floor of $17.0 million in Q1 2022.
  • Median Total Liabilities over the past 4 years was $132.4 million (2024), compared with a mean of $123.6 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 646.54% in 2023 and later fell 16.77% in 2025.
  • BioXcel Therapeutics' Total Liabilities stood at $129.1 million in 2022, then increased by 0.88% to $130.2 million in 2023, then rose by 0.94% to $131.4 million in 2024, then increased by 6.8% to $140.4 million in 2025.
  • The last three reported values for Total Liabilities were $140.4 million (Q4 2025), $133.7 million (Q3 2025), and $133.5 million (Q2 2025) per Business Quant data.